Global Green, Inc. Cites Recent Industry Studies that Reinforce Significance of Its Salmonella Vaccine, Salmogenics

TALLAHASSEE, Fla.--(BUSINESS WIRE)--Global Green, Inc. (OTCBB:GOGC) cites recent leading industry studies that emphasize how difficult Salmonella bacteria is to avoid and to eradicate. These studies reinforce the significance of the Company’s patented, exclusively licensed Salmonella vaccine, Salmogenics.

“Repeated studies over the years from multiple highly-regarded research institutions all confirm how deadly Salmonella is as well as being difficult to eradicate. Salmogenics helps to minimize the effect of this difficult to contain disease and the unique, cost-effective in-ovo vaccination method makes it easier for poultry growers to administer”

One example, a recent University of California – Irvine-led study, uncovers how Salmonella avoids the body’s immune response. Researchers identified a novel molecular mechanism that allows Salmonella to survive despite the immune system’s best efforts to destroy it.

“Repeated studies over the years from multiple highly-regarded research institutions all confirm how deadly Salmonella is as well as being difficult to eradicate. Salmogenics helps to minimize the effect of this difficult to contain disease and the unique, cost-effective in-ovo vaccination method makes it easier for poultry growers to administer,” commented Dr. Mehran Ghazvini, Chairman and CEO.

Salmogenics improves the immune system, health and welfare of the chicken, as validated by the model Efficacy Study conducted by AHPharma, on the Company’s behalf, and provides a healthier source of protein for humans in a cost effective manner. The birds tend to be healthier and experience increased weight gain and reduced mortality, a benefit to both the poultry industry and for humans.

Konky Sotomayor, DVMZ, the developer of Salmogenics, graduated with honors as a Doctor in Veterinary Medicine and Zootechny in the Veterinary Medicine Faculty in the State University of Guayaquil in Ecuador. He attended the prestigious Lantanisbruk Universitet in Uppsala, Sweden, renowned for their International Science Program. The program assists countries in strengthening their domestic research capacity within the chemical, physical and the mathematical sciences.

Dr. Sotomayor, a U.S. citizen, has worked in private laboratory-managing research and development positions since 1979. He has extensive experience in isolation of infectious diseases agents and manufacturing the corresponding vaccines.

AHPharma, Inc. is an independent research laboratory, employing research specialists with a combined more than 50 years of independent research experience, specializing in conducting microbiological, safety, efficacy, nutritional, and marketing studies for the food animal industry. They also have expertise in meeting regulatory requirements by various federal agencies for the conduct of quality research and for the product approval process.

Global Green, Inc. is a green pharmaceutical company committed to identifying technology platforms and commercializing products that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards. Salmogenics, the Company’s flagship product, was developed by Nutritional Health Institute Laboratories, LLC, a research affiliate and majority shareholder. The vaccine is currently in the final stage of the USDA approval process. For more information, visit www.globalgreeninc.org.

Forward-Looking Statement

This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that such forward-looking statements involve risks and uncertainties, which include among others, the inherent uncertainties associated with smaller reporting companies, including without limitation, other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.